Health Discovery Corp (HDVY)

[bhtaylor29]

Seems like this one got in under the radar:

http://www.epigenomics.com/en/Press_Releases/2010/datednews/100223_Darmkrebs-Bluttest_.html

Quick Link Summary:
Tuesday, 23.02.2010
Only four months after launch, Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, today reported that its blood based Septin9 test for colorectal cancer Epi proColon is now available nationwide in Germany and Switzerland. The test which is able to detect colorectal cancer in a simple blood draw is based on Epigenomics’ patented biomarker mSEPT9 and is the first blood test ever for colorectal cancer early detection offered in Europe. The test was introduced in October 2009 as a CE-marked in vitro diagnostic product in Europe. As of today, the test is offered by 16 laboratories in Germany and Switzerland making it available to doctors and patients across both countries.

Strategic diagnostics industry partners include Abbott Molecular, Sysmex Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories, Inc. for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc., in Seattle, WA, U.S.A. For more information, please visit Epigenomics’ website at www.epigenomics.com.
Epigenomics’ product portfolio contains the CE-marked IVD test Epi proColon, the world’s first regulatory cleared molecular diagnostic test for the detection of colorectal cancer in blood that is based on the biomarker Septin9, and further proprietary DNA methylation biomarkers and IVD products at various stages of development for colorectal, lung and prostate cancer. For development and global commercialization of IVD test products, Epigenomics pursues a dual business strategy in which direct commercialization of proprietary diagnostic test products is combined with non-exclusive licensing to diagnostic industry players with broad customer access. Strategic diagnostics industry partners include Abbott Molecular, Sysmex Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories, Inc. for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc., in Seattle, WA, U.S.A. For more information, please visit Epigenomics’ website at

ANNNDDD

http://www.healthdiscoverycorp.com/pr/feb22_07.html
Quick Link Summary:
Monday, February 22, 2007
According to a recent paper published in the Journal of Urology by Dr. Tom Stamey at Stanford University Medical Center, a world-renowned expert on prostate cancer, and a Member of the HDC Science Team "The Era of PSA is over" because of the low accuracy rate of Prostate Specific Antigen in identifying clinically significant prostate cancer. Dr. Stamey believes that a new more accurate test is needed to effectively detect this type of cancer. PSA sales are estimated at over $350 million annually and represent 40% of all annual cancer serum biomarker revenues.

HDC has recently signed licensing agreements with Pfizer (NYSE: PFE), Epigenomics (Frankfurt, Prime Standard: ECX) and Bruker Daltonics (NASDAQ: BRKR).


ANNDD another older link:
http://findarticles.com/p/articles/mi_m0EIN/is_2006_Sept_19/ai_n26989802/
SAVANNAH, Ga. -- Health Discovery Corporation ("HDC") (OTCBB: HDVY) today announced that it has executed a non-exclusive worldwide license agreement with Epigenomics AG ("Epigenomics"). Epigenomics will utilize HDC's Support Vector Machine ("SVM") technology in its research on DNA methylation analysis techniques. Scientists recognize that DNA methylation plays an important role in the development of cancer by silencing genes that normally control cell growth. The SVM technology will help detect changes in gene activity by measuring the differences in methylation patterns between healthy and diseased tissues. Financial terms of the deal were not disclosed.

"HDC's SVM technology will facilitate the discovery of new methylation markers in both blood and tissue for use in the early detection and clinical management of cancer patients," said Dr. Herbert A. Fritsche, Professor of Laboratory Medicine at the University of Texas M.D. Anderson Cancer Center and Chairman of HDC's Science Board. "Utilization of the SVM technology may also accelerate the discovery of companion diagnostics that predict drug response in cancer and other non-cancerous diseases."

"Epigenomics is committed to always provide the most advanced technologies to the customers of our biomarker service and collaboration business," said Kurt Berlin, Chief Science Officer of Epigenomics. "The license provided by HDC will enable Epigenomics to further expand its offerings, adding to our most comprehensive and cutting-edge technology portfolio in biomarker discovery and validation."

"The Epigenomics agreement is our second SVM licensing deal in the past six weeks, the first with Bruker Daltonics in mass spectrometry and now this one in the field of methylation," said Stephen D. Barnhill, M.D., HDC's Chairman and Chief Executive Officer. "The distinct nature of the two applications underscores the scope and power of HDC's SVM technology as the leading pattern recognition tool. Our agreement with Epigenomics is another strong endorsement of our proprietary SVM portfolio that should spark the interest of other companies in licensing this versatile and potent tool."


\\\END///// Sorry for the extremly long post.
So is ECX using HDVY's technology for the colorectal cancer test or not? And why is HDVY working on a colorectal test when its apperently been done by the very people its licensed the technology to? And ECX is also working with Quest.. I dont see how it couldnt be to be honest. Especially when both companies mention the almost exact same pharse..

Mentioned by HDVY-- "Epigenomics will utilize HDC's Support Vector Machine ("SVM") technology in its research on DNA methylation analysis"

Mentioned by ECX---Epigenomics’ product portfolio contains the CE-marked IVD test Epi proColon, the world’s first regulatory cleared molecular diagnostic test for the detection of colorectal cancer in blood that is based on the biomarker Septin9, and further proprietary DNA methylation biomarkers

DNA METHYLATION!!

Any one have thoughts on these developments? I notice that HDVY does not mention anything about ECX's test on their website, so Im guessing this was not part of the licensing agreement? And ECX doesnt mention HDVY on ITS website. I would have thought that this would be huge news for HDVY but yet there is no mention of it anywhere (or am I missing something?)...Makes my head spin!